🏢 官网IRSRPTCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:30:00时区推断·⟳ 抓取 20:33:57·⚡ 决策 07-22 20:35:11 +1m14s·96.9 天前
Sarepta将公布二季度财报并举行电话会
本信号只是Sarepta Therapeutics预告将发布2026年二季度财务结果并举行网络电话会，未披露收入、利润、指引、监管进展或产品销售等新增事实。
📄 原文SRPT↗ 原文
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
« Back Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results 07/22/26 8:30 AM EDT The event will be we…
不做 Sarepta Therapeutics（SRPT.US）
仅为二季度财报发布时间和电话会安排通知，未披露业绩、指引、产品销售或监管进展等新增事实，无法形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 high ↗
关键理由
- 本信号只是Sarepta Therapeutics预告将发布2026年二季度财务结果并举行网络电话会，未披露收入、利润、指引、监管进展或产品销售等新增事实。
- 事件本身属于投资者关系日程通知，不改变公司短期基本面预期，也无法形成同向交易催化。
主要风险
- 真正可能影响股价的是后续二季度财报和管理层电话会内容，本条通知本身没有可交易信息。
原文全文
展开原文 · 1,798 字
« Back
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
07/22/26 8:30 AM EDT
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Investor Contacts:
Ian Estepan, 617-274-4052, iestepan@sarepta.com
Ryan Wong, 617-800-4112, rwong@sarepta.com
Tam Thornton, 617-803-3825, tthornton@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
07/22/26 8:30 AM EDT
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Investor Contacts:
Ian Estepan, 617-274-4052, iestepan@sarepta.com
Ryan Wong, 617-800-4112, rwong@sarepta.com
Tam Thornton, 617-803-3825, tthornton@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。